Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
NCT ID: NCT02624869 Phase: PHASE3 Status: COMPLETED Enrollment: 163 Completion: 2021-06-01
Conditions
Familial Hypercholesterolemia
Interventions
Evolocumab
Summary
The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.
Primary Outcome
Number of Participants With Treatment-emergent Adverse Events (TEAEs)